Navigation Links
Neurocrine Biosciences Reports Second Quarter 2013 Results
Date:7/25/2013

in early July 2013. The study is a placebo-controlled, double-blind, parallel-design, multiple-dose, 12-week study assessing six-week dosing of NBI-98854 against placebo, followed by six weeks of open-label treatment with NBI-98854 in tardive dyskinesia patients with underlying schizophrenia or schizoaffective disorder. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the first six weeks of dosing. The study has incorporated a capsule formulation of NBI-98854. Top-line data from the placebo-controlled portion of this study is expected in September 2013.

The Kinect 2 Study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the AIMS at the end of the six weeks of dosing. This study continues to enroll patients, and top-line data from this study is expected in the fourth quarter of 2013.

The Company plans to request an end of Phase II meeting with the FDA for NBI-98854 in tardive dyskinesia during the fourth quarter of 2013.

The Company is also in the process of initiating two Phase I studies for NBI-98854 assessing drug-drug interactions as well as the impact of hepatic impairment on drug metabolism. Both of these studies will be completed prior to the start of Phase III and will support the planned NDA filing.

Additionally, the Company has initiated preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of these preclinical studies, the Company anticipates entering Phase I and Phase II clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Easter
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Neurocrine Biosciences Reports Third Quarter 2012 Results
6. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
8. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
10. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
11. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... first isolated in 2004 with the help of Scotch ... discover its potential applications. A single layer of carbon ... to flexible displays, graphene is strong, light, transparent, and ... we do with this new material? As researchers across ...
... International, Inc. (OTC Bulletin Board: MZEI ) (OTCQB: ... stock purchase agreement establishing a $10,000,000 equity line with Mammoth ... two-year term.  Under the terms of the agreement, Mammoth will ... the average closing bid price over a five day pricing ...
... 2010 GeneLink, Inc. (OTCBB: GNLK ), a leading consumer ... ended September 30, 2010. Highlights: ... Deloitte,s Technology Fast 500™ for the second year in a row ... Gary Beeman, GeneLink,s CEO stated, "The third quarter of ...
Cached Biology Technology:Doctoral candidate publishes on graphene's potential with NSF support 2Doctoral candidate publishes on graphene's potential with NSF support 3Doctoral candidate publishes on graphene's potential with NSF support 4Medizone International Secures $10,000,000 Funding Commitment 2Medizone International Secures $10,000,000 Funding Commitment 3GeneLink Reports Third Quarter Results 2
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... America Perimeter Security Systems Market" report to their offering. ... North American perimeter security market is estimated to grow at ... U.S. market holds a larger share in this market, ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 2012 In a study published in the March ... Academy of Child and Adolescent Psychiatry , Katherine Rice ... of Atlanta, and Emory University School of Medicine, used ... social disability in children with autism spectrum disorders (ASD) ...
... team of researchers show that most neandertals in Europe died ... a Europe populated by a stable neandertal population for hundreds ... therefore be revised. This new perspective on the ... in Molecular Biology and Evolution . The results indicate ...
... PHOENIX, Ariz. Feb. 27, 2012 The 9th ... pancreatic cancer research at the Translational Genomics Research Institute ... will go toward new international clinical trials run by ... first time that major retailers, producers and suppliers in ...
Cached Biology News:Eye-tracking reveals variability in successful social strategies for children with autism 2European Neandertals were on the verge of extinction even before the arrival of modern humans 2Celebrity Golf Classic raises $553,443 for Seena Magowitz Foundation 2
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
ANTI MYCOBACTERIUM TUBERCULOSIS...
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: